Molecular Partners AG (MOLN) Stock

About Molecular Partners AG

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG is headquartered in CH.

Molecular Partners AG (MOLN) stock trades at $3.91 with a market capitalization of $146.67M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.08, reflecting a net loss over the last twelve months, price-to-book of 1.78, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.41 and $5.36, and currently trades 27.1% below its 52-week high.

On profitability, Molecular Partners AG generates a return on equity (ROE) of -66.19% (negative, reflecting a net loss), return on capital employed of -70.20%.

Official website: www.molecularpartners.com

Molecular Partners AG by the numbers, 2016–2025

Between 2016 and 2025 Molecular Partners AG reported revenue of $23.0M rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-62.0M.

On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-64.0M.

Borrowings stand at $4.0M, cash on hand is $78.5M, cash from operations was $-51.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -32.1% over five years, and was -77.5% in the most recent year.

The share price itself has compounded at -26.6% a year over five years, -15.8% over three, 9.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Molecular Partners AG (MOLN) — frequently asked questions